Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Avrobio Inc (NQ: AVRO )

1.495 +0.035 (+2.40%)
Streaming Delayed Price Updated: 12:43 PM EDT, Jun 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Avrobio Inc

< Previous 1 2 3 Next >
AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial
From AVROBIO, Inc.
Via Business Wire
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
AVROBIO to Participate in Four Upcoming Investor Conferences in September
From AVROBIO, Inc.
Via Business Wire
AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update
From AVROBIO, Inc.
Via Business Wire
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
AVROBIO to Participate in Two Upcoming Investor Conferences in August
From AVROBIO, Inc.
Via Business Wire
AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome
From AVROBIO, Inc.
Via Business Wire
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO
Via Business Wire
AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
From AVROBIO, Inc.
Via Business Wire
AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures
From AVROBIO, Inc.
Via Business Wire
AVROBIO to Present at the H.C. Wainwright Global Investment Conference
From AVROBIO, Inc.
Via Business Wire
AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update
From AVROBIO
Via Business Wire
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting
From AVROBIO, Inc.
Via Business Wire
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference
From AVROBIO, Inc.
Via Business Wire
AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update
From AVROBIO, Inc.
Via Business Wire
AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis
From AVROBIO, Inc.
Via Business Wire
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
AVROBIO Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer
From AVROBIO, Inc.
Via Business Wire
AVROBIO to Present at Cowen’s 2nd Annual Genetic Medicines Summit
From AVROBIO, Inc.
Via Business Wire
AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022
From AVROBIO, Inc.
Via Business Wire
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
AVROBIO Reprioritizes Pipeline Programs
From AVROBIO, Inc.
Via Business Wire
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1
From AVROBIO, Inc.
Via Business Wire
AVROBIO to Present at Two Upcoming Investor Conferences in November
From AVROBIO, Inc.
Via Business Wire
AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM Conference
From AVROBIO, Inc.
Via Business Wire
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
AVROBIO Reports Third Quarter 2021 Financial Results and Provides Business Update
From AVROBIO, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.